All In Biotech

Drug Trial Radar · NCT04774536

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Aug 22, 2025

Primary completion

Mar 1, 2030

Study completion Mar 1, 2030

Sponsor

Lead sponsor
Mark Walters, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, Los Angeles; University of California, Berkeley
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

Conditions

  • Sickle Cell Disease

Interventions

  • CRISPR_SCD001Drug

    CRISPR\_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and grade 3 or higher serious adverse events, using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE)Time frame: 24 months post-transplant

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis

    Davis, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • UCSF Benioff Children's Hospital

    Oakland, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.